Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Asks CMS To Allow More Medtech Input, Longer-Term Metrics In Bundled Pay Models

Executive Summary

Industry groups told the US Medicare agency it should seek the input of a broader array of stakeholders – including medtech companies – in developing future episode-of-care pay models. They also argued that participation in the programs should be voluntary, and that the pay models should account for patient outcomes longer than 90 days following initial care. The responses came in comments to CMS following its proposal to scale back its joint replacement bundled payments program and eliminate a cardiac-care version.

You may also be interested in...



Trump Administration, Industry Want Stark Law Changes To Accommodate ACO Formation

The US administration and the medical device industry are pushing Congress to create exceptions and waivers to Stark law requirements that prohibit physician self-referrals to radiological clinics or other medical facilities in which they have a financial interest. They say the law inhibits formation of accountable care organizations fostered by the Centers for Medicare and Medicaid Services, and hinders value-based health care.

US House Panelists Fault CMS For Cutbacks To Joint Replacement Bundled-Pay Program

The US Centers for Medicare and Medicaid Services' decision last fall to limit a joint replacement bundled program met with considerable pushback from lawmakers this week.

Could CMS Changes To Bundled Pay Models Stifle Medtechs' Value-Based Pay Plans?

The US Center for Medicare and Medicaid Services proposed downsizing its CJR joint replacement value-based payment model and outright canceling its cardiac procedure bundled payment model. Will the move discourage companies like Zimmer Biomet, Johnson & Johnson, and Medtronic, which have already invested in programs based on the value-based models?

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel